论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu Y, Mu Y, Zhang A, Ren SD, Wang WH, Xie JP, Zhang YX, Zhou CH
Received 17 January 2017
Accepted for publication 14 March 2017
Published 29 March 2017 Volume 2017:10 Pages 1897—1908
DOI https://doi.org/10.2147/OTT.S132507
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Background: Immunotherapy based on cytokine-induced killer cells or combination of
dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising
clinical outcomes for treating esophageal cancer (EC). However, the clinical
benefit varies among previous studies. Therefore, it is necessary to
systematically evaluate the curative efficacy and safety of CIK/DC-CIK
immunotherapy as an adjuvant therapy for conventional therapeutic strategies in
the treatment of EC.
Materials and
methods: Clinical trials published before October 2016 and reporting CIK/DC-CIK immunotherapy
treatment responses or safety for EC were searched in Cochrane Library, EMBASE,
PubMed, Wanfang and China National Knowledge Internet databases. Research
quality and heterogeneity were evaluated before analysis, and pooled analyses
were performed using random- or fixed-effect models.
Results: This research covered 11 trials including 994 EC patients. Results of
this meta-analysis indicated that compared with conventional therapy, the
combination of conventional therapy with CIK/DC-CIK immunotherapy significantly
prolonged the 1-year overall survival (OS) rate, overall response rate (ORR)
and disease control rate (DCR) (1-year OS: P =0.0005; ORR and DCR: P <0.00001).
Patients with combination therapy also showed significantly improved quality of
life (QoL) (P =0.02). After CIK/DC-CIK
immunotherapy, lymphocyte percentages of CD3+ and CD3–CD56+ subsets (P <0.01) and cytokines levels of
IFN-γ, -2, TNF-α and IL-12 (P <0.00001) were
significantly increased, and the percentage of cluster of differentiation (CD)4+CD25+CD127– subset was significantly decreased, whereas analysis of CD4+, CD8+, CD4+/CD8+ and CD3+CD56+ did not show significant difference (P >0.05).
Conclusion: The combination of CIK/DC-CIK immunotherapy and conventional therapy is
safe and markedly prolongs survival time, enhances immune function and improves
the treatment efficacy for EC.
Keywords: cytokine-induced killer cells, dendritic cells, esophageal cancer,
immunotherapy, meta-analysis